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Short Communication
Assignment of the gene encoding for Meth A tumour
rejection antigen (TATA) to Chromosome 12 of the mouse
L.W. Law
National Cancer Institute, Bethesda, Maryland 20205, USA.
Tumours induced in the mouse by chemical
carcinogens usually express specific antigens of the
transplantation type, TATA. These antigens are
demonstrated by immunizing syngeneic hosts with
cells, purified membranes, soluble or solubilized
antigen preparations (DuBois et al., 1980; DuBois et
al., 1982; Rogers and Law, 1981; Ransom et al.,
1981; Natori et al., 1981; Pellis and Kahan, 1975)
and challenging with the same tumour. The usual
finding is that these TATAs are highly
immunogenic, stable and heritable. An intriguing
feature of these chemically induced tumours is their
uniqueness, each bearing a distinct antigen with an
absolute restriction to the tumour of origin.
Recent investigations have focused upon defining
the nature of these tumor specific antigens (TSA)
and the nature of the genes coding for TSA. Several
TATA have now been isolated and purified to
chemical homogeneity (DuBois et al., 1982). Also,
somatic cell genetic techniques have been employed
in order to define the genetic basis of antigen
diversity (Pravtcheva et al., 1981). This latter
technique has been used in studies of attempts to
assign the gene coding for the individually distinct
Meth A antigen to a particular chromosome. This
study was facilitated by the availability of a
serologic assay to detect the Meth A antigen. De
Leo et al. (1977) have recently produced a syngeneic
antiserum that defined a cell surface antigen, TSSA,
highly restricted to the methylcholanthrene-induced
sarcoma, Meth A. There now exists good evidence
that the serologically defined Meth A antigen TSSA
is closely related to the individually distinct
transplantation antigen (TATA) expressed by Meth
A (DuBois et al., 1980; DuBois et al., 1981; DeLeo
et al., 1982).
Pravtcheva et al. (1981) using somatic cell
hybrids obtained by fusing cells of Meth A and E-
36, an established cell line from Chinese hamster
lung cells, and the typing antisera produced from
Meth A immunizations, were able to assign the
Meth A antigen, TSSA, to mouse chromosome 12
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close to the genetic determinants for the Ig heavy
chain. The present study extends these findings to
show a clear correlation between chromosome 12
and Meth A antigen expression as detected by in
vivo tumour rejection assays.
BALB/c female mice, 10-12 weeks of age, were
immunized 3 times, 7 days apart with the somatic
hybrid cells and control cells listed in Table I with
a (C), then challenged 7 days after the last
immunization with Meth A sarcoma. Typical results
are shown in Figure 1. Protection against Meth A
challenge was achieved with those somatic cell
hybrids mAE 28 and ma 8c, groups 1-3, bearing the
X12 chromosome (chromosome 12 translocated to
the X chromosome, and expressing the Meth A
antigen as determined in a previous study by
Pravtcheva et al., 1981 in the serologic assay);
Table I Serologic and chromosome analysis of Meth
A x E 36 somatic cell hybrids
Meth A
Mouse chromosome antigen (TSSA)
Hybrids/controls presenta expressionb
mAE 28 x2 +C
ma 8c X12 +C
ma 12 l2 +
mAE 6 +1 2
ms 5 X _C
mAE 19 1,X c
Meth A V2 +C
E 36 -C
aChromosomes were identified by karotype and isozyme
analyses. (Pravtcheva et al., 1981).
bMeth A antigen expression determined by absorption
of anti-Meth A cytotoxic activity from antiserum;
absorption (+) in all cases was comparable with
absorption by Meth A cells. (Results adapted from
Pravtcheva et al., 1981).
cSomatic cell hybrids and control cells that were
assayed for tumour rejection in the present study.
Karyotyping and isozyme analyses were performed by Dr
D. Pravtcheva. The cells were passaged once in tissue
culture prior to being used in the tumour rejection assays.
( The Macmillan Press Ltd., 1984110 L.W. LAW
Group Immunogen
1 mAE 28 P<0.001
2 mAE 28 P<0.01











Figure 1 Inhibition of growth of Meth A sarcoma
expressed as percentage of the control tumour volume
in BALB/c recipients immunized with tissue culture
grown cells of the several somatic cell hybrids between
Meth A and E 36. Immunizations with 3 x 106 cells, 7
days apart x 3. Challenges with 2 x 104 Meth A cells,
except in group 2 where 5 x 104 Meth A cells were
used as challenge. Groups 8 and 9 are specificity
controls; group 8 was challenged with sarcoma CI-4
and group 9 with sarcoma CII-10, 5 x 105 cells for
each challenge tumour after appropriate
immunizations with mAE 28 somatic cell hybrid.
In order to stabilize the several somatic cell hybrids
and prevent loss of mouse chromosomes, these hybrid
cells were hybridized with a clone of BALB/3T3-THO
(see Pravtcheva et al., 1981). THO cells were therefore
used as negative controls for immunization. See group
6.
hybrids ms 5 bearing the X chromosome and mAE
19 bearing chromosome 1 and X and neither
expressing the Meth A TSSA (groups 4 and 5) did
not prevent growth of Meth A sarcoma. Protection
achieved with the hybrid cells bearing X12 was
similar to that achieved by immunization with
control Meth A cells, the source of the X12
chromosome. These results parallel exactly the
results obtained in the serologic assays as shown in
Table I, again showing the close relationship of
TSSA and TATA in this system. Groups 8 and 9,
Figure 1 are speciflcity assays. mAE 28-immunized
BALB/c mice challenged with CI-4 and CII-10
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Figure 2 Growth of Meth A sarcoma in immunized
BALB/c recipients: (0) ma 8c; (AL) mAE 28; (OI),
THO controls; (U), non-immunized controls.
Immunizations with 3 x 106 cells, 7 days apart x 3.
Challenge with Meth A at 2 x 104 cells, 7 days after
last immunization. Mean tumour diameters at 20 days
in parentheses. Differences between both the mAE 28
and ma 8c groups and controls=P<0.01. Eight mice
in experimental groups and 16 mice in controls.
Each of these methylcholanthrene-induced sarcomas
has its own strong TATA (Law, 1980).
Figure 2 shows typical growth patterns of the
Meth A sarcoma in controls and in mice
immunized with the somatic cell hybrids mAE 28
and ma 8C, bearing the X12 chromosome.
As shown previously using serologic assays to
detect the Meth A tumor specific antigen, only
those somatic cell hybrids (Meth A x E 36) bearing
the X12 translocation were capable of immunizing
BALB/c mice against Meth A challenge. Hybrids
containing X as a single chromosome (ms 5) or X
accompanied by chromosome 1 (mAE 19) did not
effectively immunize against Meth A sarcoma
challenge, thus paralleling the lack of Meth A
antigen expression in the serologic assay. There is
therefore a clear correlation of Meth A antigen
(TSSA and TATA) expression and the presence of
chromosome 12.
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